Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

Filter by All Topics
Molecular Oncology Tumor Board
ASCO University
Jul 13, 2016 9:27 AM
Read more to answer the following questions:

According to WHO 2016 criteria, what is the most accurate diagnosis and how do we distinguish ET from PMF in era of molecular studies? Does it matter to distinguish early primary myelofibrosis from essential thrombocythemia for management?
How would we...
ASCO International Affairs
Jun 30, 2016 12:22 PM
ASCO partnered with local organizers to hold three Multidisciplinary Cancer Management Courses (MCMC) between February and April 2016. The evaluation results for these courses indicate that the majority of respondents intend to make practice changes and gained new knowledge and skills as a result...
Molecular Oncology Tumor Board
ASCO University
Jun 15, 2016 8:26 AM
Read more to answer the following questions: 1) What is the significance of the patient having only a partial resection of an ologodendroglioma? 2) What is the importance of the 1p19q co-deletion status of the tumor?
Trainee & Early-Career Oncology
Virginia D. Anderson
May 25, 2016 2:22 PM
As we continue to make improvements to ASCOconnection.org, we want to make the Discussion section meaningful for medical students, interns, residents, fellows, and young professionals in oncology. We welcome your feedback!
What kinds of questions would you like to ask your oncology community about...
Molecular Oncology Tumor Board
ASCO University
May 11, 2016 9:46 AM
Read more to answer the following questions: 1) Would further imaging be required before discussing a plan for systemic therapy?  2) Which of the available tissue specimen/sites would be appropriate for HER2 testing: tissue from the primary resection specimen, metastasis from the para-aortic lymph...